Physician profile
Dale Whitebloom
NPI 1144310608
$7,223.62
in general payments reported to CMS, 2019-2025
35 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $388 · 2021: $447 · 2022: $1,280 · 2023: $1,024 · 2024: $1,483 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,027 · Education: $22.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,027.48 |
| Education | $22.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,104.14 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $883.27 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $822.51 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $497.06 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $491.69 | 2021-2024 | Zeposia |
| Pfizer INC. | $268.05 | 2020-2025 | |
| Madrigal Pharmaceuticals | $202.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $195.41 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $174.46 | 2019-2025 | |
| Boston Scientific Corporation | $162.17 | 2019-2025 | Cre Pro |
| Ironwood Pharmaceuticals, INC | $158.89 | 2020-2025 | Linzess |
| Genzyme Corporation | $147.20 | 2022-2025 | |
| Medtronic, INC. | $110.81 | 2021-2022 | |
| Ardelyx, INC. | $107.84 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $104.12 | 2022-2023 | Rebyota |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $96.35 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $85.49 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $65.55 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $58.49 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $55.86 | 2019-2023 | Dificid |
| Mallinckrodt Hospital Products INC. | $49.96 | 2024-2025 | Terlivaz |
| Alfasigma USA, INC. | $44.86 | 2020-2021 | |
| Celltrion USA INC. | $44.17 | 2024-2025 | Zymfentra, Vegzelma |
| Shionogi INC | $35.71 | 2019 | |
| Phathom Pharmaceuticals, INC. | $34.49 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $32.23 | 2019 | |
| Intercept Pharmaceuticals, INC. | $31.29 | 2023 | Ocaliva |
| Qol Medical, LLC | $29.28 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $23.38 | 2023 | Lesionhunter |
| Fresenius Kabi USA, LLC | $20.08 | 2024 | Idacio |
| Novo Nordisk INC | $19.51 | 2025 | Wegovy |
| Amgen INC. | $19.35 | 2023 | Amjevita |
| E.R. Squibb & Sons, L.L.C. | $17.35 | 2022 | |
| Evoke Pharma, INC. | $15.66 | 2023 | Gimoti |
| Ucb, INC. | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Whitebloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.